Recursion Pharmaceuticals Says Potential Advanced Solid Tumor Treatment Well Tolerated

MT Newswires Live12-10

Recursion Pharmaceuticals (RXRX) said late Monday that an ongoing phase 1/2 clinical study of its drug REC-617 as a potential monotherapy for the treatment of advanced solid tumors was generally well-tolerated across all dose levels.

The company said that a "confirmed durable partial response" was achieved in one of the 18 evaluable patients in the study with metastatic, platinum-resistant ovarian cancer receiving REC-617 monotherapy.

Four of the patients achieved a "best response of stable disease" in multiple dose levels for up to six months of treatment, the company said.

Recursion plans to launch the next phase of the study and initiate REC-617 combination studies next year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490060869?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490060869","market":"sh","top_or_hot":-1,"title":"Recursion Pharmaceuticals Says Potential Advanced Solid Tumor Treatment Well Tolerated","media":"MT Newswires Live","content":"<html><body><p> Recursion Pharmaceuticals (RXRX) said late Monday that an ongoing phase 1/2 clinical study of its drug REC-617 as a potential monotherapy for the treatment of advanced solid tumors was generally well-tolerated across all dose levels.</p><p>The company said that a \"confirmed durable partial response\" was achieved in one of the 18 evaluable patients in the study with metastatic, platinum-resistant ovarian cancer receiving REC-617 monotherapy.</p><p>Four of the patients achieved a \"best response of stable disease\" in multiple dose levels for up to six months of treatment, the company said.</p><p>Recursion plans to launch the next phase of the study and initiate REC-617 combination studies next year.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recursion Pharmaceuticals Says Potential Advanced Solid Tumor Treatment Well Tolerated</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecursion Pharmaceuticals Says Potential Advanced Solid Tumor Treatment Well Tolerated\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 18:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recursion Pharmaceuticals (RXRX) said late Monday that an ongoing phase 1/2 clinical study of its drug REC-617 as a potential monotherapy for the treatment of advanced solid tumors was generally well-...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490060869","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490060869","pubTimestamp":1733825005,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Recursion Pharmaceuticals  said late Monday that an ongoing phase 1/2 clinical study of its drug REC-617 as a potential monotherapy for the treatment of advanced solid tumors was generally well-tolerated across all dose levels.The company said that a \"confirmed durable partial response\" was achieved in one of the 18 evaluable patients in the study with metastatic, platinum-resistant ovarian cancer receiving REC-617 monotherapy.Four of the patients achieved a \"best response of stable disease\" in multiple dose levels for up to six months of treatment, the company said.Recursion plans to launch the next phase of the study and initiate REC-617 combination studies next year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4157":"电子设备和仪器","BK6522":"化石燃料股","RXRX":"Recursion Pharmaceuticals, Inc.","BK4539":"次新股","AEIS":"先进能源工业公司","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","BK6088":"石油天然气设备与服务","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","BLZ.SI":"爱文思控股","BK4548":"巴美列捷福持仓","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC"},"translate_title":"Recursion Pharmaceuticals表示潜在的晚期实体瘤治疗耐受性良好","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEIS":1,"BLZ.SI":1,"RXRX":1},"content_text":"Recursion Pharmaceuticals (RXRX) said late Monday that an ongoing phase 1/2 clinical study of its drug REC-617 as a potential monotherapy for the treatment of advanced solid tumors was generally well-tolerated across all dose levels.The company said that a \"confirmed durable partial response\" was achieved in one of the 18 evaluable patients in the study with metastatic, platinum-resistant ovarian cancer receiving REC-617 monotherapy.Four of the patients achieved a \"best response of stable disease\" in multiple dose levels for up to six months of treatment, the company said.Recursion plans to launch the next phase of the study and initiate REC-617 combination studies next year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490060869"}